Rituximab treatment in patients with primary Sjögren's syndrome: An open‐label phase II study

Abstract

Findings of this phase II study suggest that rituximab is effective in the treatment of primary SS. The high incidence of HACAs and associated side effects observed in this study needs further evaluation.